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Development of nanoparticles as tissue-specific drug delivery platforms can be considerably  
influenced by the complement system because of their inherent pro-inflammatory and 
tumorigenic consequences. The complement activation pathways, and its recognition 
subcomponents, can modulate clearance of the nanoparticles and subsequent inflamma-
tory response and thus alter the intended translational applications. Here, we report, for 
the first time, that human properdin, an upregulator of the complement alternative path-
way, can opsonize functionalized carbon nanotubes (CNTs) via its thrombospondin type I 
repeat (TSR) 4 and 5. Binding of properdin and TSR4+5 is likely to involve charge pattern/
polarity recognition of the CNT surface since both carboxymethyl cellulose-coated carbon 
nanotubes (CMC-CNT) and oxidized (Ox-CNT) bound these proteins well. Properdin 
enhanced the uptake of CMC-CNTs by a macrophage cell line, THP-1, mounting a 
robust pro-inflammatory immune response, as revealed by qRT-PCR, multiplex cytokine 
array, and NF-κB nuclear translocation analyses. Properdin can be locally synthesized 
by immune cells in an inflammatory microenvironment, and thus, its interaction with 
nanoparticles is of considerable importance. In addition, recombinant TSR4+5 coated 
on the CMC-CNTs inhibited complement consumption by CMC-CNTs, suggesting that 
nanoparticle decoration with TSR4+5, can be potentially used as a complement inhibitor 
in a number of pathological contexts arising due to exaggerated complement activation.
Keywords: carbon nanotubes, complement, properdin, thrombospondin repeats, phagocytosis, inflammation, 
cytokines
inTrODUcTiOn
Nanoparticles including carbon nanotubes (CNTs) are considered attractive drug delivery platforms. 
However, their intended destination post-administration and associated cytotoxicity can be signifi-
cantly altered by the innate immune system, which is likely to interact rapidly with the nanoparticles 
(1–3). A number of nanoparticles have been shown to activate a potent humoral wing of the innate 
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immunity called the complement system (4–6). The complement 
system can influence the pharmacokinetics and biodistribution 
of the therapeutic nanoparticles since complement proteins are 
potent opsonins, acting as a bridge between nanoparticles and a 
range of innate and adaptive immune cells (2, 7). This interaction 
not only brings about clearance of nanoparticles by phagocytic 
cells (8) but also influences the inflammatory response (9).
The complement system consists of more than 40 plasma 
proteins circulating in the blood and tissue fluids, many as 
inactive zymogens, which upon sequential activation help to 
defend against infection and mount an immune response (10). 
Complement activation takes place via the classical, lectin, and 
alternative pathways (Figure  1A) (10–13). In the alternative 
complement pathway, properdin is an upregulator of comple-
ment activation.
Properdin interacts with the surface-bound ligands C3b, 
C3bB, or C3bBb. Once properdin binds both C3b and Bb, the 
unstable C3 convertase, which has a half-life of about 90  s is 
strongly stabilized, its half-life increasing by 5- to 10-fold (14). 
Thus, the intermediates C3bP (where P stands for properdin) and 
C3bBP generate C3bBbP on the target surfaces (14). This allows 
the generation of C3b in an amplification loop, resulting in depo-
sition of many copies of C3b on a complement-activating surface. 
One C3b binds to C3bBb itself, forming C3bBbC3b, homologous 
to the classical pathway C5 convertase C4b2a3b, thus leading to 
C5 cleavage and lytic pathway (10).
The C3 activation cascade is downregulated on host cells by 
membrane-bound regulatory proteins: complement receptor 
1 (CR1), membrane cofactor protein (MCP) and decay accel-
erating factor (DAF), soluble factor H and factor I. Factor H 
inhibits C3bBb formation by binding to C3b; C3b in the factor 
H–C3b complex is cleaved by factor I to iC3b. In addition, factor 
H enhances the decay of convertase activity by displacing Bb 
from the complex, thus inhibiting the activation of complement 
alternative pathway (15). CR1, factor H, and DAF bind to C3b 
and dissociate the Bb fragment, while factor H, CR1 and MCP 
are cofactors for the factor I-mediated cleavage of C3b to iC3b, 
thus preventing the amplification of activation of complement on 
the host cell surface. Complement facilitates the recognition by 
phagocytic cells of complement-activating particles via bound 
complement components, which are recognized by the receptors 
CR1, CR2, CR3, CR4, and CRIg. CR1, expressed on macrophages 
and neutrophils, binds C3b, leading to phagocytosis in the pres-
ence of immune mediators such as C5a (10, 16).
Properdin is found at a concentration of 25 µg/mL in plasma 
(17). Due to this low level, its local production by a variety of 
stimulated cells, such as neutrophils, endothelial cells, peripheral 
blood monocytes, dendritic cells, and T cells, may be important 
in localized activation of the alternative pathway (18). Properdin 
is made up of identical subunits of 53 kDa associating with each 
other in a head-to-tail manner (19, 20) to form cyclic polymers 
(dimers, trimers, and tetramers) dispersed in a ratio of 26:54:20 
(21). The human properdin monomer has seven thrombospon-
din type I repeats (TSR; TSR0–TSR6). A typical TSR is 60 amino 
acids long and has sequence similarities with thrombospondin, 
circumsporozoite protein of malaria parasite, and a domain of 
complement component C9 (22, 23) (Figure 1B). TSR4 and TSR5 
in properdin play an important role in binding to C3b and in the 
stabilization of C3 convertase (24–26).
Carbon nanotubes and their functionalized derivatives can 
activate complement via the classical and alternative pathways 
(4–6). Complement deposition can enhance their uptake by 
complement receptor-bearing macrophages and B  cells, while 
downregulating the pro-inflammatory response that is otherwise 
induced by CNTs (8, 9). We have shown previously that C1q, the 
recognition subcomponent of the classical pathway, and factor 
H, the downregulator of the alternative pathway, can bind CNTs 
directly (8). The structural organization of properdin (multi-
subunit, multiple potential binding domains, and potential mul-
tivalency) appears to suggest a possible role as a soluble pattern 
recognition receptor (PRR). It has been shown that properdin 
can bind apoptotic T cells via sulfated glycosaminoglycan (GAG) 
and augment phagocytosis by macrophages (27). Furthermore, 
properdin can also bind to DNA exposed on apoptotic and 
necrotic cells in a C3b-independent manner (28). Recently, it 
has been shown that properdin locally produced by DCs and 
tolerogenic DCs can bind to bind to necrotic cells, confirming 
previous  reports to implicate properdin as an independent rec-
ognition molecule. Furthermore, treatment of DCs with siRNA 
targeting properdin reduced the proliferation of allogenic T cells, 
and this effect was more pronounced when combined with IFN-γ 
stimulation. Interestingly, IFN-γ reduced the production of prop-
erdin and factor H in both types of DCs (29). This demonstrates 
that local production of properdin is crucial for the DC and 
T  cell responses. Furthermore, the production of properdin by 
neutrophils (29, 30) was comparable to DCs, whereas factor H 
production was very low (29).
Macrophages of properdin-deficient mice have reduced M1 
phenotype (IL-1β) and an increased production in the M2 phe-
notype (arginase-1, MCP-1, and IL-10) associated with tumour- 
promoting activity. This suggests that the deficiency in properdin 
can modulate macrophages toward an M2 phenotype, which 
enhances the tumor environment (31).
Properdin binds to surfaces of several pathogens such as 
Neisseria gonorrhoeae (32), Salmonella typhimurium lipopolysac-
charide (LPS), Neisseria meningitidis lipooligosaccharide (33), 
and Chlamydia pneumoniae (34), which leads to complement 
activation (15). In addition, recombinant properdin enhanced 
the opsonization of N. meningitidis and S. pneumonia by human 
serum in vitro (16). Properdin also binds to Zymosan, Escherichia 
coli (E. coli) strains, live human leukemia T cell lines, and rabbit 
erythrocytes, suggesting that properdin binding to these surfaces 
demonstrates its role as a PRR, initiating alternative pathway on 
target surfaces.
Properdin binds to NKp46 expressed on NK cells and innate 
lymphoid cell (ILC)1 and ILC3. The control of infection by prop-
erdin was dependent on NKp46 and group 1 ILCs. The control 
of meningococcal infection was not dependent on membrane 
attack complex, further confirming the pattern recognition role 
of properdin (35).
Here, we show that properdin acts as a pattern recognition 
receptor, binds to CNTs, via at least domains TSR4+5, and 
enhances their phagocytosis by macrophages (opsonizes), in 
addition to promoting a robust pro-inflammatory immune 
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FigUre 1 | Continued
FigUre 1 | (a) Schematic diagram of the three pathways of the complement system, highlighting the upregulator (properdin) and downregulator (factor H) of the 
alternative pathway. The three complement systems, the classical, alternative, and lectin pathways merge in C5 convertase. C5 convertase cleaves C5 forming C5b, 
which combines with C6, C7, C8, and C9 to form the membrane attack complex (MAC). Activation of the classical pathway occurs upon recognition and binding of 
targets via C1q, which in turn activates C1r and C1s, and C1s cleaves C4 and C2. The lectin pathway is activated when mannose-binding lectin (MBL) or ficolins 
bind to microbial surfaces or other targets, and this binding activates MBL-associated serine proteases (MASPs), similar to C1s, which cleave C4 and C2. Classical 
and lectin pathway cleaved products of C4 and C2 form C3 convertase (C4bC2a), which cleaves C3 into C3b, the major opsonin of the complement system, binds 
covalently to targets. C3b also binds to C4b2a, altering its substrate preference to cleave C5 and thus forming C5 convertase C4b2a3b, which cleaves C5 into C5a 
and C5b. C5b assembles with C6, C7, C8, and C9 to form the MAC, which can cause disruption or lysis of target cells. The alternative pathway C3 convertase 
C3bBb is a homolog of C4b2a. It is formed by slow hydrolysis of C3 to form C3(H2O), which is similar to C3b in conformation. C3(H2O) forms a complex with factor 
B (FB), and FB in the complex is cleaved to form C3(H2O)Bb, plus Ba, by factor D (FD). C3(H2O)Bb itself cleaves C3 to form C3a plus C3b, and C3b then reacts with 
FB and FD to form C3bBb, in the same way as C3(H2O)Bb is formed. C3bBb is unstable, but is stabilized by properdin, which holds together the C345C domain in 
C3b and the vWF domain in Bb, and also repositions the thioester-containing domain in C3b that is involved in the decay process of C3 convertase.  
(B) Representative diagram of the modular organization of human properdin including thrombospondin repeats. Properdin is found in serum as monomers,  
dimers, trimers, and tetramers of a polypeptide made up of seven thrombospondin type I repeat (TSR) domains. It enhances alternative pathway activation by 
stabilization of C3 and C5 convertases. TSR0 is the N-terminal TSR. TSR4 and TSR5 modules expressed in tandem in E. coli have also been depicted.
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response. The main C3b-binding domains of properdin, TSR4 
and TSR5, when coated together on CNTs, acted as a potent 
inhibitor of complement alternative pathway activation, raising 
the possibility of regulating inflammatory response and comple-
ment activation on synthetic material surfaces.
MaTerials anD MeThODs
expression and Purification  
of recombinant human Properdin  
in human embryonic Kidney (heK) cells
Full-length human properdin gene was subcloned as an EcoRI-
XbaI cassette into pSecTag-C (Life Technologies), using terminal 
primers 5′-GAATTCGACCCCGTGCTCTGCTTCAC-3′ and 
5′-TCTAGAGAGTTCCTCTTCC TCAGGGTCTTTG-3′, yield-
ing the construct pLK-FL. The cDNA clone of human properdin 
was used as a template in the PCR reaction that was originally 
isolated from U937 cells stimulated by PMA and subcloned in the 
pBluescript vector (19, 24). HEK cells were plated in 24-well plates 
at a concentration of 0.5–1.25 × 105 cells per well in 0.5 mL of com-
plete DMEM-F12 medium [10% v/v fetal calf serum (FCS), 2 mM 
l-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin] 
and left at 37°C, 5% CO2 in humidified atmosphere. Once the cells 
reached about 80% confluence, the growth medium was replaced 
with fresh 0.5 mL/well of complete DMEM-F12 medium. Up to 
5 µg of pLK-FL DNA in 100 µL of Opti-MEM® I Medium (Gibco) 
without serum was added to each well for transfection. Up to 
1.75 µL of Lipofectamine LTX® Reagent (Invitrogen) was added 
into the above-diluted Opti-MEM®-DNA solution, mixed gently, 
and incubated for 30  min at room temperature to form DNA-
Lipofectamine LTX® Reagent complexes, 100  µL of which was 
added directly to each well containing HEK cells, swirled gently, 
and incubated at 37°C in CO2 incubator for up to 24  h before 
examining for protein expression and secretion. Supernatant 
was collected and tested for the presence of properdin by direct 
ELISA.
Recombinant full-length properdin was purified by passing 
the supernatant through an antiproperdin IgG (monoclonal) 
affinity column, kindly provided by Dr. C. Koch, State Serum 
Institute, Copenhagen, Denmark. The column (anti-Properdin-
Sepharose) was washed with three bed volumes of HEPES buffer 
(10 mM HEPES, 140 mM NaCl, 0.5 mM EDTA, pH 7.4). Bound 
properdin was eluted in 1 mL fractions using 3 M MgCl2. The 
peak fractions were dialyzed against HEPES buffer overnight 
at 4°C. Minor contaminants were further removed by applying 
the dialyzate on to a DEAE Sepharose ion exchange column 
(GE Healthcare), which was first equilibrated with three bed 
volumes of Tris buffer (50 mM Tris–HCl, pH 7.5, 50 mM NaCl, 
5 mM EDTA). Properdin did not bind to the DEAE Sepharose and 
was recovered in the flow-through, whereas other contaminants 
remained bound to the resin. SDS-PAGE analysis was carried out 
to confirm the purity of recombinant properdin.
expression and Purification  
of recombinant human Tsr4+5  
Modules in Tandem, Fused to  
Maltose-Binding Protein in E. coli
Recombinant human TSR4+5 fused with maltose-binding 
protein (MBP) was expressed using E. coli BL21 strain (Life 
Technologies) (26). Overnight primary bacterial cultures were 
grown in Luria-Bertani medium with 100 µg/mL ampicillin with 
shaking (200 rpm) at 37°C until an A600 of 0.6–0.8 was reached. 
Expression was then induced with 0.4  mM isopropyl β-d-
thiogalactoside (Sigma) and continued for 3 h at 37°C. The cell 
pellet, recovered after centrifugation at 4,500 rpm for 10 min, was 
resuspended in lysis buffer (20 mM Tris–HCl, pH 8.0, 0.5 M NaCl, 
1 mM EDTA, 0.25% v/v Tween 20, 5% v/v glycerol) containing 
100 µg/mL lysozyme (Sigma) and 0.1 mM phenylmethanesulfo-
nyl fluoride (Sigma) and incubated for 1  h at 4°C on a rotary 
shaker. The lysate was then sonicated (using a Soniprep 150; MSE, 
London, UK) at 60 Hz for 30 s with an interval of 2 min on ice 
(12 cycles). The sonicate was centrifuged at 10,000 g for 15 min at 
4°C. The supernatant was collected and diluted 5-fold with buffer 
I (20 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.25% 
v/v Tween 20) and passed through an amylose resin column (New 
England Biolabs), previously equilibrated in buffer I. The affinity 
column was washed with buffer I without Tween 20 and with 1 M 
NaCl, followed by buffer II (20 mM Tris–HCl, pH 8.0, 100 mM 
NaCl, 1 mM EDTA). The TSR4+5 fusion protein was then eluted 
with buffer II containing 10 mM maltose (Sigma). Minor con-
taminants were further removed by applying the fusion protein 
to a Q-Sepharose column (Sigma) equilibrated with three column 
volumes of low-salt buffer (50 mM Tris–HCl, pH 7.5, 100 mM 
NaCl, 5 mM EDTA, pH 7.5). After extensive washing with low-salt 
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buffer, the fusion protein was step eluted with 200 mM NaCl. The 
peak fractions were then passed through Pierce™ High Capacity 
Endotoxin Removal Resin to remove LPS. Endotoxin levels in 
the purified protein samples were analyzed using the QCL-1000 
Limulus amebocyte lysate system (Lonza). The assay was linear 
over a range of 0.1–1.0 EU/mL (10 EU = 1 ng of endotoxin), and 
the endotoxin levels were <5 pg/µg of the recombinant proteins. 
MBP protein used as a control was expressed in E. coli using 
pMal-c vector (New England Biolab) and purified, as described 
above for MBP-TSR4+5.
Preparation and Transmission electron 
Microscopy (TeM) of carboxymethyl 
cellulose-coated carbon nanotubes 
(cMc-cnTs)
The synthesis and characterization of double-walled carbon 
nanotubes (DWNTs) has been described earlier (36, 37). After 
catalyst elimination by non-oxidizing HCl treatment, the DWNTs 
were washed with deionized water. For functionalization, wet 
DWNTs (corresponding to a dry amount of 100 mg) were added 
to a solution of 100 mg of carboxymethyl cellulose (CMC; Sigma 
21901) in PBS. After mixing, the suspension was freeze dried to 
obtain a 50:50 homogeneous dry mixture of DWNTs and CMC. 
The samples were resuspended in PBS + 5 mM EDTA pH 7.4, and 
then centrifuged at 8,000 g for 5 min for the removal of aggregates. 
After centrifugation, the non-sedimented CNTs were washed to 
remove excess CMC by vacuum filtration using 0.2 µm Whatman 
polycarbonate filter with PBS-EDTA, pH 7.4. Functionalized 
CNTs (CMC-CNTs) were then resuspended in PBS-EDTA. For 
oxidized DWNTs, 100  mg of DWNTs were added to 100  mL 
of HNO3 (3  M) and placed in ultrasonic bath for 30  min and 
refluxed at 130°C for 24 h. The solution was left to cool at room 
temperature. The solution was washed and filtered on a polypro-
pylene membrane (0.45 μm). For electron microscopy, 2 µL of 
well-dispersed CMC-CNTs were adsorbed onto carbon-coated 
grids. Micrographs were recorded using a JEOL 2100 FEG-TEM 
operating at 80 Kv, and the images were processed using Gatan 
microscopy suite software (Gatan, Inc.). Surface visualization of 
CMC-CNTs was performed using a Zeiss Supra 35vP scanning 
electron microscope operating at 5 kev.
coating of cMc-cnTs and Ox-cnTs  
with Properdin and Tsr4+5
Purified properdin, TSR4+5, MBP, or BSA (Bovine serum albu-
min) were incubated in a w/w ratio of 2:1 with 100 µg of CMC-
CNTs or Ox-CNTs in the affinity buffer (50 mM Tris–HCl, pH 
7.5, 150 mM NaCl, 5 mM CaCl2), overnight at 4°C. Excess protein 
was removed by repeated centrifugation and washing at 17,000 g 
for 10 min to wash away any unbound proteins trapped within 
the CNTs. CNTs were redispersed in affinity buffer between 
centrifugations.
Western Blotting to Detect Protein  
Binding to cnTs
Carbon nanotubes with bound protein were run on SDS-PAGE 
under reduced conditions, and protein bands were transferred 
on to a nitrocellulose membrane in transfer buffer (25 mM Tris, 
192 mM glycine, 20% v/v methanol, pH 8.3) at 320 mA for 2 h. 
The membrane was then blocked with 5% semi-skimmed milk 
powder (Tesco, UK) in PBS, pH 7.4 (Sigma) overnight at 4°C. 
Rabbit anti-human properdin (0.92  mg IgG/mL) polyclonal 
antibodies were diluted 1:500 in PBS and incubated with the 
membrane for 2  h at room temperature. The membrane was 
washed three times, 10 min each, with PBS + 0.05% Tween 20 
(PBST). Protein A–horseradish peroxidase (1:1,000; Thermo 
Scientific) in PBS was added and left at room temperature for 
1  h. The blot was washed again with PBST three times, and 
the color was developed using 3,3′-diaminobenzidine (DAB) 
(Sigma-Aldrich).
complement consumption assays
To measure complement consumption in human serum via the 
alternative pathway, properdin, TSR4+5, or MBP were precoated 
on CMC-CNTs in 1:1  w/w ratio in affinity buffer overnight at 
4°C, followed by washing, as described above to remove unbound 
protein. Protein-coated CMC-CNTs and zymosan (positive con-
trol) were incubated with human serum (1/5 dilution) in DGVB-
Mg-EGTA buffer (2.5 mM sodium barbital, 71 mM NaCl, 7 mM 
MgCl2, 10 mM EGTA, 2.5% w/v glucose, 0.1% gelatin, pH 7.4) for 
1 h at 37°C. Serum diluted 1/5 and incubated with no additions 
was the negative control. After incubation, CNTs were removed 
by centrifugation at 17,000 g for 10 min, and the ability of the 
supernatant to lyse rabbit erythrocytes (TCS Biosciences) was 
tested. Rabbit erythrocytes were washed by repeated centrifuga-
tion for 10 min, 700 g in PBS + 5 mM EDTA, pH 7.4 until the 
supernatant was clear. The cell concentration was adjusted to 
1 × 109/mL in DGVB-Mg-EGTA. Then, 100 µL of these rabbit 
erythrocytes was added to 100 µL of serum supernatant samples 
or to undiluted normal human serum and incubated for 1 h at 
37°C. After incubation, cells were centrifuged (700  g, 10  min) 
and released hemoglobin in the supernatant was measured at 
541 nm. Total hemolysis (100%) was measured by lysing rabbit 
erythrocytes with undiluted normal human serum. Background 
spontaneous hemolysis was determined by incubating rabbit 
erythrocytes with DGVB-Mg-EGTA buffer. Percentage comple-
ment consumption was calculated using (C −  Ci)/C ×  100%, 
where C represents the % hemolysis of the negative control, and 
Ci is the % hemolysis with the CMC-CNT- or zymosan-treated 
sample.
To check whether the CMC-CNTs with bound properdin 
retained capacity to activate the complement alternative pathway, 
we used properdin-deficient serum obtained from the properdin 
gene-deficient mice (38). Genotyped mice were bled under 
terminal anesthesia. Blood was spun, and serum was transferred 
to a tube and stored at −20°. Properdin-coated CMC-CNTs 
(Properdin-CNT), TSR-coated CMC-CNTs (TSR4+5-CNT), and 
CMC-CNT alone were incubated with properdin-deficient serum 
(1/2 dilution) in DGVB-Mg-EGTA buffer and incubated for 1 h 
at 37°C. After incubation, CNTs were removed by centrifugation 
at 17,000 g for 10 min, and serum was collected. To each of the 
collected sera, purified properdin (1 µg/mL) was added, and the 
reconstituted sera were tested for the lysis of rabbit erythrocytes, 
as described above.
TaBle 1 | Terminal primers used for qPCR analysis.
Targets Forward primer reverse primer
18S ATGGCCGTTCTTAGTTGGTG CGCTGAGCCAGTCAGTGTAG
IL-1β GGACAAGCTGAGGAAGATGC TCGTTATCCCATGTGTCGAA
IL-6 GAAAGCAGCAAAGAGGCACT TTTCACCAGGCAAGTCTCCT
IL-10 TTACCTGGAGGAGGTGATGC GGCCTTGCTCTTGTTTTCAC
IL-12 AACTTGCAGCTGAAGCCATT GACCTGAACGCAGAATGTCA
TGF-β GTACCTGAACCCGTGTTGCT GTATCGCCAGGAATTGTTGC
TNF-α AGCCCATGTTGTAGCAAACC TGAGGTACAGGCCCTCTGAT
NF-κB GTATTTCAACCACAGATGGCACT AACCTTTGCTGGTCCCACAT
NLRP3 GCCATTCCCTGACCAGACTC GCAGGTAAAGGTGCGTGAGA
6
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Biotinylation of cMc-cnTs
Carboxymethyl cellulose-coated carbon nanotubes were bioti-
nylated as follows: 1 mg of CMC-CNTs was suspended in 1 mL 
0.1 M MES buffer [2-(N-morpholino) ethanesulfonic acid, pH 5]. 
1 mg of pentylamine biotin (Pierce, Thermo Fisher Scientific) in 
the presence of 4 µg EDC [1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide] was added to the CMC-CNT suspension and 
stirred for 2  h at room temperature. The reaction was stopped 
by adding 50  µL of 0.1  M ethanolamine (Sigma). The result-
ing biotin-CMC-CNTs were dialyzed extensively against PBS 
(pH 7.4) to remove remaining reactants and MES.
Uptake of cMc-cnT into ThP-1 cells, 
Observed by Fluorescence Microscopy
Uptake of biotinylated CMC-CNTs, coated with properdin or 
MBP-TSR4+5, was examined using differentiated THP-1 mac-
rophages. For fluorescence microscopy, 1 × 105 THP-1 cells were 
plated on 13-mm coverslips and treated for 24 h with 100 nM 
Phorbol myristate acetate (PMA; Sigma) in complete RPMI 
1640 containing 10% v/v FCS, 2  mM l-glutamine, 100  U/mL 
penicillin, 100 µg/mL streptomycin, and 1 mM sodium pyruvate. 
Differentiated THP-1 cells were washed three times with PBS to 
remove excess PMA and then rested for 24 h in complete RPMI 
1640 as above prior to exposure to the CNTs. Cells were washed 
three times with PBS and were exposed to 4 µg/mL biotinylated 
CMC-CNT coated with properdin (Properdin-CNTs), MBP-
TSR4+5 (TSR4+5-CNT), or biotin-CMC-CNTs alone in 500 µL 
of serum-free RPMI 1640 medium for 2  h. Cells were washed 
twice with PBS, fixed with 4% paraformaldehyde for 10  min, 
washed, and processed for fluorescence microscopy. The cells 
on coverslips were permeabilized using permeabilizing buffer 
(20 mM HEPES, pH 7.4, 300 mM sucrose, 50 mM sodium chlo-
ride, 3 mM MgCl2, 0.5% Triton X-100) for 5 min on ice. The cells 
were then stained for 30 min with 1.6 µM Hoechst 33342 (Life 
Technology), 2  µg/mL Alexa-Fluor546-conjugated wheat germ 
agglutinin (Invitrogen) and Alexa fluor 488-conjugated streptavi-
din (Thermo Scientific) to reveal biotinylated CMC-CNTs. Cells 
were washed twice, mounted using Citifluor anti-fade (Citifluor, 
UK), and observed under a Nikon Eclipse TE2000-S confocal 
microscope with 62 X oil lens.
To observe nuclear translocation of NF-κB, permeabilized cells 
were incubated with rabbit anti-NF-κB p65 polyclonal antibodies 
(Santa Cruz Biotech), followed by secondary Alexa Fluor 488-
goat anti rabbit antibody, and observed with Leica Fluorescent 
microscope using LAS software (Leica Microsystems).
For quantification, 5 × 105 THP-1 cells were plated in 12-well 
plates and differentiated with PMA for 24 h and rested for 24 h in 
complete RPMI media. Cells were washed with PBS and exposed 
with 4  µg/mL biotinylated CMC-CNT coated with properdin 
(Properdin-CNTs), MBP-TSR4+5 (TSR4+5-CNT), or biotin-
CMC-CNTs alone in 500 µL of serum-free RPMI 1640 medium 
for 2 h. Cells were washed three times with PBS and lysed with 
lysis buffer (10 mM HEPES, 20 mM NaCl, 0.5 mM EDTA, 1% 
v/v Triton X 100). An ELISA type assay was employed to quantify 
the amount of CNTs taken up by THP-1 cells (6). Microtiter wells 
(NUNC, polysorb) were coated with 100 µL Avidin (Pierce) at 
50 µg/mL in 0.1 M carbonate bicarbonate buffer, pH 9 (Sigma) 
for 1  h at RT, followed by blocking with 0.05% of BSA for 
1  h at RT. 50  µL of a solution or cell lysate containing biotin-
CMC-CNTs and 50 µL of 0.05% BSA were added in each well 
and incubated for 1 h at RT. The plate was washed with PBS to 
remove unbound CNTs, and then incubated with 1:2,000 dilution 
of Streptavidin-HRP (Sigma) for 1 h at RT. Following washing 
again, O-phenylenediamine dihydrochloride (Sigma) was used 
as a substrate for the HRP, and the yellow 2, 3-diaminophenazine 
product was read at 450 nm.
Measurement of ThP-1 cell cytokine  
and Transcription Factor mrna 
expression Using Quantitative rT-Pcr
In a 12-well cell culture plate (Nunc), THP-1 cells (1 × 106/well) 
were differentiated with 100 nM PMA in RPMI 1640 complete 
medium for 24  h and then rested (without PMA) for 24  h. 
Cells were washed three times with PBS prior to the addition of 
10 µg/mL of properdin-CMC-CNT, MBP-TSR4+5-CMC-CNT, or 
CMC-CNT alone to wells in serum-free RPMI 1640 medium 
and incubated for 30, 60, 120, or 360  min. Cells at each time 
point were washed with PBS and lysed within the wells using 
lysis buffer from GenElute Mammalian Total RNA Purification 
Kit (Sigma-Aldrich). Total RNA was extracted from the lysate 
using the GenElute Mammalian Total RNA Purification Kit 
(Sigma-Aldrich). To inactivate both DNase I and RNase, samples 
were heated at 70°C for 10  min and subsequently chilled on 
ice. A NanoDrop 2000/2000c spectrophotometer (Thermo-
Fisher Scientific) was used to determine the amount and purity 
(260/280  nm ratio) of RNA. The cDNA was synthesized using 
High Capacity RNA to cDNA Kit (Applied Biosystems). Primers 
(Table 1) were designed using Primer-BLAST.1
The qPCR reaction mixture included 5 µL Power SYBR Green 
MasterMix (Applied Biosystems), 75  nM forward and reverse 
primers and 500 ng template cDNA in a 10 µL reaction volume. 
PCR was performed using a Step One Plus Real-Time PCR 
System (Applied Biosystems). Human 18S rRNA target was used 
as an endogenous control. Data were analyzed using the Step One 
software v2.3 (Applied Biosystems). Ct (cycle threshold) values 
for each cytokine target gene were calculated. Relative expression 
of each cytokine target gene was calculated using the relative 
1 http://blast.ncbi.nlm.nih.gov/Blast.cgi.
FigUre 2 | Transmission electron microscopy (TEM) images of pristine and 
carboxymethyl cellulose-coated carbon nanotubes (CMC-CNTs). High-
resolution TEM image of (a) pristine DWCNTs and (B) CMC-coated DWCNTs. 
Images were acquired at the same magnification. Black arrows indicate 
examples of places where the carboxymethyl cellulose (CMC) coating on the 
nanotubes is easily visible. In general, after CMC coating, the image seems 
blurred and shows much less details. Double-walled carbon nanotubes were 
coated with CMC and dispersed in water. Suspended CMC-CNTs were 
adsorbed on a carbon grid. The images were recorded with a Jeol 2100 
transmission electron microscope operating at 80 kV. Scale bar is 100 nm.
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quantification (RQ) value, using the equation RQ =  2−ΔΔCt for 
each cytokine target gene and comparing relative expression 
with that of the 18S rRNA constitutive gene product. Assays were 
conducted in triplicate.
Multiplex cytokine array analysis
Supernatant from THP-1 cells, incubated with non-biotinylated 
CMC-CNT, properdin-CMC-CNT, and MBP-TSR4+5-CMC-
CNT for 24 and 48  h, were collected for measuring secreted 
cytokines, chemokines, growth factors, and other ligands and 
receptors. The analytes were measured using MagPix Milliplex 
kit (EMD Millipore) following the manufacturer’s protocol. 25 µL 
of assay buffer was added to each well of a 96-well plate, followed 
by addition of 25 µL of standard, control, or supernatant of THP-1 
cells. 70 µL of a mixture of 36 individual capture magnetic beads 
was added to 3.5 mL of diluent buffer, vortexed, and 25 µL of the 
magnetic beads coupled to analytes were added to each well con-
taining assay buffer, samples, and controls and incubated for 18 h 
at 4°C. The plate was washed with assay buffer, and 25 µL of detec-
tion antibodies (EMD Millipore) were incubated with the beads 
for 1 h at room temperature. 25 µL of streptavidin–phycoerythrin 
was then added to each well and incubated for 30 min at room 
temperature. Following the washing step, 150 µL of sheath fluid 
was added to each well, and the plate was read using the Luminex 
Magpix instrument. Assays were carried out in duplicate.
statistical analysis
Statistical analysis was conducted using GraphPad Prism ver-
sion 7.0 (GraphPad Software). An unpaired two-sided t-test 
and multiple t-test using Holm–Sidak method was used on the 
data for any significant difference between uncoated and protein 
coated CNTs. P values were computed and graphs compiled and 
analyzed.
resUlTs
recombinant Full-length Properdin  
and MBP-Tsr4+5 Bind cMc-cnTs
Functionalized DWNTs were well dispersed in aqueous solution. 
High-resolution TEM images of pristine DWCNTs (Figure 2A) 
and CMC-coated DWCNTs (Figure  2B) revealed the places 
where the CMC coating on the nanotubes was easily visible. 
In general, following CMC coating, the image seems blurred and 
shows much less details.
We analyzed the binding of purified properdin as well as 
TSR4+5 modules (Figure 3A) to CNTs after preincubation of 
the proteins with CMC-CNTs followed by washing with PBS 
extensively via centrifugation. Western blot analysis revealed 
that properdin and MBP-TSR4+5 bound CMC-CNTs and 
appeared in the 12% SDS-PAGE at their expected molecular 
weight at ~55kDa (Figure 3B). CNTs remained in the loading 
wells. Furthermore, properdin and TSR4+5 also bound to 
Ox-CNTs efficiently (data not shown). This suggested that the 
properdin and TSR4+5 interaction with CNTs is likely to be 
through charge pattern/polarity recognition of the CNT surface 
and not due to CMC.
MBP-Tsr4+5 coated on cMc-cnTs 
inhibited complement consumption  
via the alternative Pathway
Properdin-coated and MBP-TSR4+5-coated CMC-CNTs were 
assessed for their ability to activate the complement alternative 
pathway (Figure  4A) compared with uncoated CMC-CNTs. 
Zymosan was used as a positive control that consumed comple-
ment. Properdin coating of CMC-CNT did not interfere with the 
alternative pathway activation; it allowed complement consump-
tion by the CNTs to the same extent as CMC-CNT alone. MBP 
also did not diminish consumption. However, TSR4+5-coated 
CMC-CNTs showed ~60% less complement consumption, sug-
gesting that the CNT-surface bound TSR4+5 acted as an inhibitor 
of the complement alternative pathway, similar to its inhibitory 
properties in solution (26). These results suggest that properdin is 
likely to bind to CNTs via TSR4+5 and that precoated TSR4+5 can 
inhibit the binding of properdin (from the serum), and thereby 
FigUre 3 | Carboxymethyl cellulose-coated carbon nanotubes (CMC-CNTs) 
stably bind to purified human properdin and recombinant TSR4+5, as shown 
via SDS-PAGE (a) and western blot (B). (a) CMC-CNTs were incubated with 
recombinant human properdin, or thrombospondin type I repeat (TSR) 
4 + 5-MBP fusion protein and BSA overnight in the affinity buffer. Carbon 
nanotubes (CNTs) were washed extensively via centrifugation and run on an 
SDS-PAGE (12%) under reduced conditions. Properdin migrated at ~55 kDa 
and MBP-TSR4+5 migrated as a single band at ~53 kDa. (B) In parallel, the 
SDS-PAGE was transferred onto nitrocellulose membrane for 2 h at 320 mA. 
The blot was probed with anti-human properdin (polyclonal) antibodies, 
followed by protein A–HRP conjugate and developed using 
3,3′-diaminobenzidine.
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diminish alternative pathway activation. Properdin-coated CMC-
CNTs also consumed complement (activated complement) via 
the alternative pathway (Figure  4B) when properdin-deficient 
serum was used. Complement consumption was increased by 
~60% compared to uncoated CMC-CNTs. TSR4+5-coated CNTs 
were not significantly different in consumption from uncoated. 
This suggested that the CNT-bound properdin still retained its 
activity of promoting alternative pathway activation.
Figure 4 suggests that properdin binding is a dominant factor in 
alternative pathway activation by CMC-CNT. In Figure 4A (using 
normal human serum), it is shown that CMC-CNT, P-CMC-CNT, 
and MBP-CMC-CNT all consume about 60% of the (alternative 
pathway) complement activity in the serum, whereas TSR4+5-
CMC-CNT consume only about 15%. In Figure 4B (properdin-
deficient mouse serum), only P-CMC-CNT allow extensive 
consumption: CMC-CNT and TSR4+5 CMC-CNT show much 
lower consumption. Therefore, properdin (on the P-CMC-CNT) 
has a very large effect.
Properdin, but not Tsr4+5, enhanced 
cMc-cnT Uptake by ThP-1 cells
Although properdin and TSR4+5 bound to nanoparticles, only 
full-length properdin, and not TSR4+5, was able to enhance 
uptake of CNTs by differentiated THP-1 cells at 2 h (Figure 5) 
in the absence of added complement (serum). Previous studies 
have reported an enhanced phagocytosis of nanoparticles in a 
complement-dependent and complement-independent manner. 
Precoating with C1q enhanced uptake of CNTs by U937 monocytic 
cells and human monocytes, whereas factor H, a negative regulator 
of the complement system, did not (8). As shown in Figure 5, 
Alexa Fluor 488-conjugated streptavidin-labeled biotin-CMC-
CNT (green) did not show a significant level of uptake at 2  h. 
Properdin-CMC-CNT showed considerably enhanced uptake by 
THP-1 cells, compared to CMC-CNT alone and TSR4+5-CMC-
CNT. The CMC-CNTs (green) were observed within the cell 
membrane stained with Alexa Fluor 546-conjugated wheat germ 
agglutinin (red) and the nucleus (Hoechst, blue). The qualitative 
confocal sections (right panel) with higher magnification revealed 
properdin-CMC-CNT within the cell; however, very few CMC-
CNTs could be seen intracellularly in the case of TSR4+5-CMC-
CNT (Figure 5), suggesting that an intact properdin molecule is 
required for this function as an “opsonin.” This also indicates that 
interaction of properdin with macrophage may not be limited to 
TSR4+5 only, and other TSR modules may be involved.
Pro-inflammatory cytokines are 
Upregulated by Properdin-coated  
cMc-cnTs, as revealed by qPcr analysis
Having found properdin acting as an opsonin for CNTs, we next 
examined the pro- and anti-inflammatory cytokine response 
by THP-1 cells via qPCR analysis. TNF-α, IL-1β, IL-6, and 
IL-12 mRNA expression were significantly upregulated at 6 h by 
properdin-CMC-CNT and TSR4+5, and CMC-CNTs from 30 min 
onward (Figure 6A). In contrast, IL-10 and TGF-β were initially 
upregulated at 30 min, but decreased by 6 h, suggesting that the anti-
inflammatory response was dampened (Figure  6B). Consistent 
with the upregulation of TNF-α, NF-κB was also upregulated by 
6  h, when CMC-CNTs were coated with properdin or TSR4+5. 
However, the NLRP3 mRNA expression was not significant, sug-
gesting that the activation of NLRP3 inflammasome was weak.
Multiplex array analysis revealed 
Dramatic Upregulation of Pro-
inflammatory cytokines/chemokines by 
ThP-1 cells When challenged with cMc-
cnTs coated with Properdin or Tsr4+5
Multiplex array analysis using supernatants that were collected 
at 24 and 48 h time points from the phagocytosis assay revealed 
a dramatic increase in the levels of pro-inflammatory cytokines 
(IL-6, IL-12p40, IL-12p70, IL-1α, IL-1β, TNF-α, IL-13, IL-15, 
and IL-9) for properdin-CMC-CNT or TSR4+5-CMC-CNT. 
Properdin and TSR4+5-coated CMC-CNTs also enhanced che-
moattractants such as IL-8, I-TAC, MIG, and MCP-1 (Figure 7). 
A number of anti-inflammatory cytokines, chemokines, growth 
factors, and immune ligands were also differentially upregulated 
by protein-coated CNTs (Figure 7).
Properdin or Tsr4+5-coated cMc-cnTs 
induced nuclear Translocation of nF-κB  
in ThP-1 cells
THP-1 cells were used to assess the translocation of NF-κB fol-
lowing challenge with Properdin-CMC-CNT or TSR4+5-CMC-
CNT, using fluorescent staining. The transcription factor, NF-κB, 
regulates the signaling pathway of many pro-inflammatory 
FigUre 4 | (a) Carboxymethyl cellulose-coated carbon nanotube (CMC-CNT) bound properdin activates the alternative pathway, while thrombospondin type I 
repeat (TSR)4 + 5-coated carbon nanotubes (CNTs) fail to consume complement: Properdin, TSR4+5, or maltose-binding protein (MBP)-coated CMC-CNTs were 
incubated with human serum (1/5 dilution in DGVB-Mg-EGTA buffer) for 1 h at 37°C. Samples were spun down, and serum was collected for consumption assay. 
Zymosan without CNTs was used as a positive control, and serum alone without CNTs was used as a negative control (zero consumption). (B) Only properdin-
coated CNTs allow complement consumption in the presence of properdin-deficient serum derived from properdin gene knockout mice. Protein-coated CMC-CNTs 
were incubated with properdin-deficient serum diluted (1:2) with DGVB-Mg-EGTA buffer for 1 h at 37°C. The samples were centrifuged and properdin-deficient 
serum supernatant was collected. Properdin was added to the serum to give a final concentration of 1 µg/mL. Serum with reconstituted properdin was assayed for 
complement consumption. The experiments were repeated three times; error bars represent ± SD. A two-tailed, unpaired t-test was performed on the data to 
determine significant differences in complement consumption of properdin coated CNTs and TSR4+5-coated CNTs with CNTs only. All these comparisons were 
significant (P < 0.05), except where shown [not significant (ns), P > 0.05].
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cytokines when exposed to external stimuli. Properdin-CMC-
CNT or TSR4+5-CMC-CNT incubated with THP-1 cells at 2 h 
were fluorescently stained with an antibody against the p65 subunit 
of NF-κB (green) (Figure  8). The merged image shows induc-
tion of translocation of NF-κB to the nucleus (blue), which is 
significantly enhanced by properdin-CMC-CNT and TSR4+5-
CMC-CNT, compared to CMC-CNT alone (Figure 8). Properdin 
and TSR4+5-coated CMC-CNTs also induced an upregulation of 
NF-κB mRNA levels at 360 min by THP-1 cells (Figure 6B). This is 
consistent with the nuclear localization of NF-κB (Figure 7). This 
reflects on the upregulation of the pro-inflammatory response by 
TNF-α, IL-1β, IL-2, and IL-6 (Figures 6 and 7).
DiscUssiOn
Previous reports have established an important role for the 
classical pathway in the recognition and phagocytic clearance 
of functionally derivatized CNTs (6, 8). CNTs, pristine and 
derivatized, appeared to offer a molecular charge pattern for 
C1q to bind and activate the classical pathway. On its own, C1q 
appeared to bind CNTs via its globular head (gC1q) domain, 
enhanced uptake of CNTs by macrophages, and upregulated 
the pro-inflammatory immune response (8). Although com-
plement factor H also bound to derivatized CNTs, it did not 
enhance uptake while exerting an anti-inflammatory effect. 
CNTs, coated with recombinant forms of globular head mod-
ules corresponding to the C-terminal ends of the A, B, and C 
chains of C1q [ghA, ghB, and ghC, respectively (39)], were able 
to inhibit classical pathway activation via the nanoparticle sur-
face. In addition, they also enhanced uptake of CNTs leading to 
considerable downregulation of a pro-inflammatory response. 
Thus, nanoparticles precoated with recombinant globular heads 
have been proposed to be a good strategy to avoid quick clear-
ance of nanotherapeutics by phagocytes due to complement 
deposition with concomitant suppression of pro-inflammatory 
cytokine/chemokine response (8). Here, we have examined 
whether properdin can interact with nanoparticles, thus poten-
tially acting as a pattern recognition innate immune molecule, 
similar to C1q and factor H, and modulate CNT handling by 
macrophages.
FigUre 5 | (a) Properdin-coated carboxymethyl cellulose-coated carbon nanotube (CMC-CNT) show enhanced uptake by THP-1 cells. To observe internalization 
of carbon nanotubes (CNTs), PMA-differentiated THP-1 cells were treated with properdin or MBP-TSR4+5-coated biotinylated CMC-CNTs and uncoated 
biotinylated CMC-CNTs for 2 h. Cells were washed, fixed, permeabilized, and stained with Alexafluor-488-labeled Streptavidin (green) to reveal internalized 
biotin-CMC-CNTs (arrows). Alexafluor546-conjugated wheat germ agglutinin was used to reveal plasma membrane (red), and the nucleus was stained with Hoechst 
33342 (Blue). Images shown are single sections (including side images) taken with a Nikon confocal microscope; scale bar, 20 µm arrow heads point to the CNTs 
adhering to the plasma membrane. (B) TSR4+5-coated CNTs show reduced uptake by THP-1 cells. To quantify the amount of uptake of protein coated or 
uncoated CMC-CNTs, THP-1 cells were incubated with 4 µg/mL of protein-coated biotin CMC-CNTs or uncoated CMC-CNTs for 2 h. The cells were lysed, and the 
amount of CNTs was quantified by an ELISA type assay. All experiments were done in triplicate; error bars represent mean ± SEM. A two-tailed, unpaired t-test was 
performed on the data to determine significant differences in uptake of CNTs between properdin-coated CNTs and TSR4+5-coated CNTs with CNTs only. All these 
comparisons were significant (P < 0.05), except where shown [not significant (ns), P > 0.05].
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Pluronic-corona nanoparticles stimulate complement activa-
tion via the alternative pathway. The hydroxyl-containing nano-
particles are strong activators of C3, and the core thiols enhance 
the release of C3a (40, 41). Fe MWNTs coated with CMC, RNA 
or PL-PEG-NH2 activate both the classical (predominantly) and 
alternative pathways (6). The consumption of C3 and C5 on the 
CNT surface suggests that there would be binding sites for C4b 
and C3b. C3b and C4b bind to nucleophilic groups, such as OH, 
and NH2 groups; however, C3b does not form covalent adducts 
with high-molecular-weight proteins when bound to CNT. Thus, 
it may bind via hydrophobic interactions with CNTs or covalently 
to unesterified cholesterol in adsorbed HDL. Serum opsoniza-
tion or complement deposition enhanced the uptake of CNTs by 
macrophages compared to non-opsonized CNTs, leading to an 
anti-inflammatory cytokine response (6).
Properdin is a highly positively charged molecule at neutral 
pH, with an isoelectric point of >9.5 (21). It binds to several 
self and non-self-target ligands such as Zymosan (42), rabbit 
erythrocytes, N. gonorrhoeae (32), T cells (27), human proximal 
tubular epithelial cells (43), and cartilage oligomeric matrix 
protein (44). Properdin engagement with surface-bound C3b 
recruits more C3b to form the C3 convertase complex, C3bBb. 
Properdin has also been proposed to act as a pattern recognition 
molecule for initiating alternative pathway other than just stabi-
lizing the already formed C3bBb convertase (14). Properdin can 
directly interact with target ligands such as GAGs (28), including 
heparin (45), heparan sulfate (27, 46), dextran sulfate, fucoidan 
(47), and chondroitin sulfate (27). Properdin binding to activated 
platelets appears to occur via surface GAGs; when surface GAGs 
are removed, there is reduction in properdin binding to acti-
vated platelets (48). Properdin can bind DNA on late apoptotic 
and necrotic cells (42) and also bacterial LPS (33). Properdin’s 
direct interaction with cell surface molecules may indicate it is a 
selective pattern recognition molecule. Thus, properdin may be 
a key innate immune molecule that can bind to a wide range of 
nanotherapeutics.
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Nanoparticles are hydrophobic but are made biocompatible 
by coating with CMC, which is negatively charged, making the 
particles water soluble, less toxic, and more biodegradable and 
biotolerable (49). Many cell surface molecules identified so far 
that interact directly with properdin are negatively charged. Properdin 
and TSR4+5 were able to bind CNTs (CMC-CNT and Ox-CNT) 
directly and stably (Figure  3), in a conformation that retained 
their biological activity (Figure 4). We next assessed the uptake 
of properdin-CMC-CNT and TSR4+5-CMC-CNT by THP-1 
macrophages (Figure 5). Properdin, but not TSR4+5, was able 
to enhance the phagocytosis of nanoparticles considerably. It is 
likely that the properdin-mediated enhancement of phagocytosis 
requires additional TSR modules or multimers of properdin. This 
may be due to the requirement for additional receptors or more 
widespread engagement of receptors binding to whole properdin. 
Although uptake of nanoparticles was exclusive to properdin, 
TSR4+5 was also able to trigger the pro-inflammatory cytokine 
response similar to properdin. This may indicate that additional 
receptors need to be engaged for phagocytic uptake, which are 
not necessarily required for the cytokine response. CMC-CNTs 
on their own were not able to produce a significant signal for these 
cytokines; however, IL-10 mRNA was upregulated at 30  min, 
which may be dampening the activation of macrophages, thus 
explaining lesser uptake of uncoated CMC-CNTs alone. TNF-α, 
IL-1β, and IL-6 transcripts were dramatically upregulated at 6 h, 
suggesting that properdin or TSR4+5 coated CMC-CNTs may 
alter the immune response. Once the early response of nanopar-
ticles was revealed by qPCR, we further analyzed the secreted 
cytokine levels at 24 and 48 h following THP-1-CMC-CNT inter-
action, using multiplex array analysis (Figure  7). Interestingly, 
a dramatic upregulation of pro-inflammatory cytokine response 
was observed consistent with the early mRNA response for 
TNF-α, IL-1β, and IL-6 (Figure  6), which are potent inducers 
of GM-CSF (50). GM-CSF was dramatically upregulated by 
FigUre 6 | Continued
FigUre 6 | Transcriptional upregulation of pro-inflammatory cytokines by properdin or thrombospondin type I repeat (TSR)4 + 5-coated carboxymethyl cellulose-
coated carbon nanotubes (CMC-CNTs). For the measurement of mRNA expression of (a) pro- and (B) anti-inflammatory target genes, THP-1 cells were incubated 
with coated and uncoated CMC-CNTs for 30 min, 1 h, 2 h, and 6 h (X-axis). The expression of cytokines was measured using real-time qPCR, and the data were 
normalized using as endogenous control; 18S rRNA gene expression assays were conducted in triplicate. Error bars represent ±SEM. A multiple t-test using 
Holm–Sidak method was performed to determine significance differences in expression between each uncoated and protein-coated carbon nanotubes (CNTs) of 
different time points. All these comparisons were significant: *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001.
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Properdin-CMC-CNT as well as TSR4+5-CMC-CNT. GM-CSF 
is produced by macrophages in response to immune stimuli, 
which can recruit neutrophils and lymphocytes. IL-1α and IL-1β 
(Figure  7) induce an inflammatory pathway initiated via Myd88 
activation and triggered by NF-κB transcription of inflammatory 
genes. In addition, IL-8, a chemoattractant for neutrophils, may 
induce local production of properdin by neutrophils and enhance 
activation of the alternative pathway (30).
Although nanoparticles are considered highly promising 
drug delivery platforms in a variety of disease conditions, their 
systemic administration into the human body and their intended 
target tissue can be affected by innate and adaptive immune 
components. It has been shown in many studies that CNTs 
potently activate complement. Complement deposition leads 
to enhanced particle uptake by complement receptor-bearing 
macrophages and B  cells (9). Subsequently, it was found that 
complement deposition on CNTs was in fact advantageous due 
to suppression of the pro-inflammatory response and upregula-
tion of anti-inflammatory cytokine production (9). Functionally 
derivatized CNTs (CMC-CNT and RNA-CNT) activated 
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FigUre 7 | Continued
complement and became coated with complement proteins 
when treated with serum, while gold nanowires of similar size 
(51) were found to be poor activators of complement, while 
mounting a robust pro-inflammatory response, in contrast to 
complement-activating nanoparticles. We have shown here 
that properdin can act as an opsonin for nanoparticles without 
involving complement recruitment and activation and enhance 
their uptake and clearance by a macrophage cell line. It is possible 
that THP-1 cells synthesize a sufficient quantity of complement 
proteins (e.g., C3) to contribute to this apparent opsonization. 
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FigUre 7 | Continued
The World Protein Atlas2 reports that Properdin RNA and 
trace C3 RNA is found in these cells. However, Takizawa et al. 
found that the addition of serum as a complement source 
was necessary to observe phagocytosis of apoptotic cells by 
2 http://www.proteinatlas.org.
activated THP-1 cells (52). In addition, we have shown comple-
ment deposition on CNTs invariably modulates an otherwise 
pro-inflammatory response toward anti-inflammatory immune 
response dominated by IL-10 (9). Interesting, pulmonary 
surfactant protein SP-D can also opsonise CNTs and induce a 
potent pro-inflammatory response by macrophages. However, 
SP-D bound CNTs, when treated with serum, continued to 
FigUre 7 | Properdin or thrombospondin type I repeat (TSR)4 + 5-coated carboxymethyl cellulose-coated carbon nanotubes (CMC-CNTs) induce secretion of 
pro-inflammatory cytokines and chemokines by THP-1 cells. Protein-coated carbon nanotubes (CNTs) were incubated with THP-1 cells for 30 min, 1 h, 2 h, 6 h, 
12 h, 24 h, and 48 h. Cells from early time points (30 min, 1 h, 2 h, and 6 h) were used for quantitative expression of different cytokines. Supernatant from late time 
points (24 and 48 h) (X-axis) were used for the measurement of the levels of cytokines (IL-6, IL-10, IL12p40, IL12p70, IL-1α, IL-1β, TNF-α, IL-15, IL-17A, IL-9, and 
TNF-β), chemokines (MCP-3, MDC, eotaxin, fractalkine, GRO, IL-8, IP-10, MCP-1, MIP-1α, and MIP-1β), growth factors (IL-2, FGF-2, G-CSF, GM-CSF, IL-3, and 
VEGF), and related ligands and receptors (IFN-γ, FLT-3L, IL-1RA, and sCD40L) by using a commercially available MagPix Milliplex kit (EMD Millipore). A multiple 
t-test using Holm–Sidak method was performed to determine significance differences in expression between expression between properdin or TSR4+5-coated and 
uncoated nanoparticles of different time points. All these comparisons were significant (P < 0.05), except where shown [not significant (ns), P > 0.05].
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FigUre 8 | Carboxymethyl cellulose-coated carbon nanotubes (CMC-CNTs) 
coated with properdin or thrombospondin type I repeat (TSR) 4 + 5 cause 
translocation of transcription factor NF-κB from cytoplasm to nucleus of 
THP-1 cells (arrows in merged images). Differentiated THP-1 cells were 
treated with properdin-coated or TSR4+5-coated CMC-CNTs for 2 h. Cells 
were washed, fixed, permeabilized, and incubated with rabbit anti-NF-κB 
p65 antibodies, followed by secondary Alexa Fluor 488-goat anti-rabbit 
antibody (Green). The nucleus was stained with Hoechst 33342 (Blue). Scale 
bar: 20 µm. Hoechst 33342 was used to stain the nucleus instead of DAPI.
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